LIVIVO - Search results -

Search results

Result 1 - 10 of total 51

Search options

Book: The assessment and treatment of addiction

Danovitch, Itai / Mooney, Larissa J.

best practices and new frontiers

2019

Author's details	edited by Itai Danovitch, Larissa J. Mooney
Language	English
Size	xii, 240 Seiten, Illustrationen
Publisher	Elsevier Mosby
Publishing place	St. Louis, Missouri
Publishing country	United States
Document type	Book
HBZ-ID	HT019986903
ISBN	978-0-3235-4856-4 ; 0-3235-4856-3
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2019 A 375	available for loan (reading room)	Lesesaal EG

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Addiction

Danovitch, Itai / Mariani, John J.

(The psychiatric clinics of North America ; 35,2)

2012

Author's details	guest ed. Itai Danovitch ; John J. Mariani
Series title	The psychiatric clinics of North America ; 35,2 Psychiatric clinics of North America
Collection	Psychiatric clinics of North America
Language	English
Size	XIV S., S. 279 - 555 : Ill., graph. Darst., Kt.
Publisher	Saunders an imprint of Elsevier
Publishing place	Philadelphia, PA
Publishing country	United States
Document type	Book
HBZ-ID	HT017310008
ISBN	978-1-4557-3926-4 ; 1-4557-3926-X
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Se 550 -35,2-	verfügbar in Königswinter	Königswinter

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Post-traumatic stress disorder and opioid use disorder: A narrative review of conceptual models.

Danovitch, Itai

Journal of addictive diseases

2016 Volume 35, Issue 3, Page(s) 169–179

Abstract: Post-traumatic stress disorder is highly prevalent among individuals who suffer from opioid use disorder. Compared to individuals with opioid use disorder alone, those with post-traumatic stress disorder have a worse course of illness, occupational ... ...

Abstract	Post-traumatic stress disorder is highly prevalent among individuals who suffer from opioid use disorder. Compared to individuals with opioid use disorder alone, those with post-traumatic stress disorder have a worse course of illness, occupational functioning, and physical health. The neurobiological pathways underlying each disorder overlap substantially, and there are multiple pathways through which these disorders may interact. This narrative review explores evidence underpinning 3 explanatory perspectives on comorbid post-traumatic stress disorder and opioid use disorder: The opioid susceptibility model (a.k.a.: the Self-Medication Hypothesis), the post-traumatic stress disorder susceptibility model, and the common factors model. Diagnostic implications, treatment implications, and directions for future research are discussed.
MeSH term(s)	Humans ; Models, Neurological ; Models, Psychological ; Opioid-Related Disorders/complications ; Opioid-Related Disorders/physiopathology ; Opioid-Related Disorders/psychology ; Self Medication/psychology ; Stress Disorders, Post-Traumatic/complications ; Stress Disorders, Post-Traumatic/physiopathology ; Stress Disorders, Post-Traumatic/psychology
Language	English
Publishing date	2016-07
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1077616-3
ISSN	1545-0848 ; 1055-0887
ISSN (online)	1545-0848
ISSN	1055-0887
DOI	10.1080/10550887.2016.1168212
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1696: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improving Emergency Department Flow for Patients Requiring Involuntary Psychiatric Hospitalization.

Bhalla, Ish / Danovitch, Itai

Psychiatric services (Washington, D.C.)

2019 Volume 70, Issue 9, Page(s) 855

MeSH term(s)	Adult ; Commitment of Mentally Ill ; Emergency Service, Hospital/organization & administration ; Emergency Service, Hospital/standards ; Hospitalization ; Humans ; Los Angeles ; Mental Disorders/therapy
Language	English
Publishing date	2019-07-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	1220173-x
ISSN	1557-9700 ; 1075-2730
ISSN (online)	1557-9700
ISSN	1075-2730
DOI	10.1176/appi.ps.70801
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 416: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The addiction consultation service for hospitalized patients with substance use disorder: An integrative review of the evidence.

Danovitch, Itai / Korouri, Samuel / Kaur, Harlene / Messineo, Gabrielle / Nuckols, Teryl / Ishak, Waguih W / Ober, Allison

Journal of substance use and addiction treatment

2024 , Page(s) 209377

Abstract: Introduction: The Addiction Consultation Service has emerged as a model of care for hospitalized patients with substance use disorder. The aim of this integrative review is to characterize the Addiction Consultation Service in general hospital settings, ...

Abstract	Introduction: The Addiction Consultation Service has emerged as a model of care for hospitalized patients with substance use disorder. The aim of this integrative review is to characterize the Addiction Consultation Service in general hospital settings, assess its impact on clinical outcomes, identify knowledge gaps, and offer guidance for implementation. Methods: We conducted an integrative review of studies from January 2002 to August 2023, applying specific inclusion criteria to collect study design, service characteristics, staffing models, utilization, and health outcomes. Additionally, a comprehensive quality appraisal was conducted for all studies considered for inclusion. Results: Findings from 41 studies meeting inclusion criteria were synthesized and tabulated. Study designs included six reports from three randomized controlled trials, five descriptive studies, and 30 observational studies. The most common study setting was the urban academic medical center. Studies evaluated the structure, process, and outcomes of the Addiction Consultation Service. A majority of studies, particularly those utilizing more rigorous designs, reported positive outcomes involving medication initiation, linkage to post-discharge care, and utilization outcomes. Conclusions: The Addiction Consultation Service care model improves quality of care for hospitalized patients with substance use disorder. Additional research is needed to assess its effectiveness across diverse medical settings, determine the effectiveness of varying staffing models, demonstrate impactful outcomes, and establish funding mechanisms to support sustainability.
Language	English
Publishing date	2024-04-22
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2949-8759
ISSN (online)	2949-8759
DOI	10.1016/j.josat.2024.209377
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The Addiction Benefits Scorecard: A Framework to Promote Health Insurer Accountability and Support Consumer Engagement.

Danovitch, Itai / Kan, David

Journal of psychoactive drugs

2017 Volume 49, Issue 2, Page(s) 122–131

Abstract: Health care insurance plans covering treatment for substance use disorders (SUD) offer a wide range of benefits. Distinctions between health plan benefits are confusing, and consumers making selections may not adequately understand the characteristics or ...

Abstract	Health care insurance plans covering treatment for substance use disorders (SUD) offer a wide range of benefits. Distinctions between health plan benefits are confusing, and consumers making selections may not adequately understand the characteristics or significance of the choices they have. The California Society of Addiction Medicine sought to help consumers make informed decisions about plan selections by providing education on the standard of care for SUD and presenting findings from an expert analysis of selected health plans. We developed an assessment framework, based on criteria endorsed by the American Society of Addiction Medicine, to rate the quality of SUD treatment benefits offered by a sample of insurance plans. We convened an expert panel of physicians to rate 16 policies of 10 insurance providers across seven categories. Data from published resources for 2014 insurance plans were extracted, categorized, and rated. The framework and ratings were summarized in a consumer-facing white paper. We found significant heterogeneity in benefits across comparable plans, as well as variation in the characterization and clarity of published services. This article presents findings and implications of the project. There is a pressing need to define requirements for SUD benefits and to hold health plans accountable for offering quality services in accordance with those benefits.
MeSH term(s)	California ; Choice Behavior ; Consumer Behavior ; Cross-Sectional Studies ; Humans ; Insurance Carriers/statistics & numerical data ; Insurance, Health/statistics & numerical data ; Social Responsibility ; Standard of Care ; Substance-Related Disorders/economics ; Substance-Related Disorders/rehabilitation ; United States
Language	English
Publishing date	2017-03-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	392405-1
ISSN	2159-9777 ; 0279-1072
ISSN (online)	2159-9777
ISSN	0279-1072
DOI	10.1080/02791072.2017.1296210
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1121: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.

IsHak, Waguih William / Garcia, Paloma / Pearl, Rachel / Dang, Jonathan / William, Catherine / Totlani, Jayant / Danovitch, Itai

Innovations in clinical neuroscience

2023 Volume 20, Issue 4-6, Page(s) 39–48

Abstract: Objective: This systematic review aims to evaluate the impact of psilocybin on patients experiencing psychiatric symptoms, with a focus on health-related quality of life (HRQoL) and safety.: Method of research: Following the Preferred Reporting Items ...

Abstract	Objective: This systematic review aims to evaluate the impact of psilocybin on patients experiencing psychiatric symptoms, with a focus on health-related quality of life (HRQoL) and safety. Method of research: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched the PubMed database and identified studies published from January 2011 to December 2021 pertaining to the impact of psilocybin on psychiatric symptoms. Two authors independently conducted a focused analysis and reached a final consensus on five studies meeting the specific selection criteria. Study bias was addressed using the Cochrane risk of bias tool. Results: The impact of psilocybin on psychiatric symptoms was examined in five randomized controlled trials (RCTs). Four studies administered 1 to 2 doses of psilocybin, with doses ranging from 14mg/70kg to 30mg/70kg, and one study administered a fixed dose of 25mg to all participants. Administration of psilocybin resulted in significant and sustained reduction in symptoms of anxiety and depression, enhanced sense of wellbeing, life satisfaction, and positive mood immediately after psilocybin administration and up to six months after conclusion of treatment. All studies included some form of psychotherapy, and none reported serious adverse effects. Conclusion: RCTs show the efficacy of psilocybin in the treatment of anxiety and depression symptoms, as well as improvement in HRQoL, and no serious side effects. However, additional research is necessary to characterize predictors of treatment response, patient screening requirements, effectiveness in broader clinical populations, and guidelines for psilocybin-assisted psychotherapy.
Language	English
Publishing date	2023-06-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2675366-2
ISSN	2158-8341 ; 2158-8333
ISSN (online)	2158-8341
ISSN	2158-8333
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Contextual barriers and enablers to establishing an addiction-focused consultation team for hospitalized adults with opioid use disorder.

Evans, Sandra K / Ober, Allison J / Korn, Ariella R / Peltz, Alex / Friedmann, Peter D / Page, Kimberly / Murray-Krezan, Cristina / Huerta, Sergio / Ryzewicz, Stephen J / Tarhuni, Lina / Nuckols, Teryl K / E Watkins, Katherine / Danovitch, Itai

Addiction science & clinical practice

2024 Volume 19, Issue 1, Page(s) 31

Abstract: Background: Hospitalization presents an opportunity to begin people with opioid use disorder (OUD) on medications for opioid use disorder (MOUD) and link them to care after discharge; regrettably, people admitted to the hospital with an underlying OUD ... ...

Abstract	Background: Hospitalization presents an opportunity to begin people with opioid use disorder (OUD) on medications for opioid use disorder (MOUD) and link them to care after discharge; regrettably, people admitted to the hospital with an underlying OUD typically do not receive MOUD and are not connected with subsequent treatment for their condition. To address this gap, we launched a multi-site randomized controlled trial to test the effectiveness of a hospital-based addiction consultation team (the Substance Use Treatment and Recovery Team (START)) consisting of an addiction medicine specialist and care manager team that provide collaborative care and a specified intervention to people with OUD during the inpatient stay. Successful implementation of new practices can be impacted by organizational context, though no previous studies have examined context prior to implementation of addiction consultation services (ACS). This study assessed pre-implementation context for implementing a specialized ACS and tailoring it accordingly. Methods: We conducted semi-structured interviews with hospital administrators, physicians, physician assistants, nurses, and social workers at the three study sites between April and August 2021 before the launch of the pragmatic trial. Using an analytical framework based on the Consolidated Framework for Implementation Research, we completed a thematic analysis of interview data to understand potential barriers or enablers and perceptions about acceptability and feasibility. Results: We interviewed 28 participants across three sites. The following themes emerged across sites: (1) START is an urgently needed model for people with OUD; (2) Intervention adaptations are recommended to meet local and cultural needs; (3) Linking people with OUD to community clinicians is a highly needed component of START; (4) It is important to engage stakeholders across departments and roles throughout implementation. Across sites, participants generally saw a need for change from usual care to support people with OUD, and thought the START was acceptable and feasible to implement. Differences among sites included tailoring the START to support the needs of varying patient populations and different perceptions of the prevalence of OUD. Conclusions: Hospitals planning to implement an ACS in the inpatient setting may wish to engage in a systematic pre-implementation contextual assessment using a similar framework to understand and address potential barriers and contextual factors that may impact implementation. Pre-implementation work can help ensure the ACS and other new practices fit within each unique hospital context.
MeSH term(s)	Humans ; Opioid-Related Disorders/therapy ; Referral and Consultation/organization & administration ; Hospitalization ; Patient Care Team/organization & administration ; Adult ; Male ; Female ; Interviews as Topic
Language	English
Publishing date	2024-04-26
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Randomized Controlled Trial ; Multicenter Study
ZDB-ID	2492632-2
ISSN	1940-0640 ; 1940-0640
ISSN (online)	1940-0640
ISSN	1940-0640
DOI	10.1186/s13722-024-00461-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures.

Hassamal, Sameer / Miotto, Karen / Dale, William / Danovitch, Itai

The American journal of medicine

2018 Volume 131, Issue 11, Page(s) 1382.e1–1382.e6

Abstract: Tramadol is commonly prescribed for pain control because it presents a lower risk for addiction and respiratory depression compared to other opioids. However, tramadol's serotonin and norepinephrine reuptake inhibitory effects result in a unique adverse ... ...

Abstract	Tramadol is commonly prescribed for pain control because it presents a lower risk for addiction and respiratory depression compared to other opioids. However, tramadol's serotonin and norepinephrine reuptake inhibitory effects result in a unique adverse effect profile. Two such adverse events are serotonin syndrome and seizures. The prevalence of tramadol-induced serotonin syndrome and seizures is modest in the general population, but if left untreated, the morbidity and mortality can be high; therefore, prompt recognition and management is essential. Various risk factors such as medical comorbidities, use or abuse of supratherapeutic doses of tramadol, and concomitant administration of proconvulsant serotonergic cytochrome P-450 inhibitors will help clinicians identify individuals at an elevated risk for serotonin toxicity and seizures. Serotonin syndrome and seizures can be effectively treated by administering benzodiazepines, providing supportive care, and discontinuing tramadol and other contributing agents. Cyproheptadine should be administered in moderate to severe cases of serotonin syndrome. Our objective is to summarize the literature on the pharmacology, epidemiology, risk factors, clinical presentations, and evidence-based management of tramadol-related seizures and serotonin syndrome.
MeSH term(s)	Analgesics, Opioid/adverse effects ; Anticonvulsants/therapeutic use ; Humans ; Risk Factors ; Seizures/chemically induced ; Serotonin Syndrome/chemically induced ; Serotonin Syndrome/complications ; Serotonin Syndrome/diagnosis ; Serotonin Syndrome/drug therapy ; Tramadol/adverse effects
Chemical Substances	Analgesics, Opioid ; Anticonvulsants ; Tramadol (39J1LGJ30J)
Language	English
Publishing date	2018-05-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	80015-6
ISSN	1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
ISSN (online)	1555-7162 ; 1873-2178
ISSN	0002-9343 ; 1548-2766
DOI	10.1016/j.amjmed.2018.04.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.289: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis.

Chernoff, Robert Alan / Messineo, Gabrielle / Kim, Sungjin / Pizano, Demetria / Korouri, Samuel / Danovitch, Itai / IsHak, Waguih William

Psychosomatic medicine

2022 Volume 84, Issue 5, Page(s) 560–580

Abstract: Objective: The purpose of this systematic review and meta-analysis was to evaluate the ability of psychosocial interventions to reduce depression and anxiety, improve quality of life, and reduce hospitalization and mortality rates in patients with heart ...

Abstract	Objective: The purpose of this systematic review and meta-analysis was to evaluate the ability of psychosocial interventions to reduce depression and anxiety, improve quality of life, and reduce hospitalization and mortality rates in patients with heart failure. Methods: Studies of psychosocial interventions published from 1970 to 2021 were identified through four databases (PubMed, Ovid MEDLINE, PsycINFO, Cochrane). Two authors independently conducted a focused analysis and reached a final consensus on the studies to include, followed by a quality check by a third author. A risk of bias assessment was conducted. Results: Twenty-three studies were identified, but only 15 studies of mostly randomized controlled trials with a total of 1370 patients with heart failure were included in the meta-analysis. Interventions were either cognitive behavioral therapy (CBT) or stress management. The pooled intervention effect was in favor of the intervention for depression (combined difference in standardized mean change [DSMC]: -0.41; 95% confidence interval [CI] = -0.66 to -0.17; p = .001) and anxiety (combined DSMC: -0.33; 95% CI = -0.51 to -0.15; p < .001) but was only a trend for quality of life (combined DSMC: 0.14; 95% CI = -0.00 to 0.29; p = .053). Evidence was limited that interventions produced lower rates of hospitalization (5 of 5 studies showing a beneficial effect) or death (1 of 5 with a beneficial effect). Conclusions: CBT and stress management interventions significantly reduced depression and anxiety compared with control conditions. CBT significantly improved quality of life compared with controls, but stress management did not. Longer treatment duration seemed to be an important factor related to treatment success.
MeSH term(s)	Anxiety/therapy ; Depression/therapy ; Heart Failure/therapy ; Humans ; Morbidity ; Psychosocial Intervention ; Quality of Life
Language	English
Publishing date	2022-03-31
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Systematic Review ; Research Support, Non-U.S. Gov't
ZDB-ID	3469-1
ISSN	1534-7796 ; 0033-3174
ISSN (online)	1534-7796
ISSN	0033-3174
DOI	10.1097/PSY.0000000000001073
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui I Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito